GeneTex, Inc. began operations in 1997 with a focus on producing high-quality antibodies for breast cancer research and has since expanded to offer antibodies for infectious disease, neuroscience, epigenetics, and signal transduction.
GeneTex utilizes recombinant monoclonal antibody technology to deliver consistent, lot-to-lot reproducible research reagents.